These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21851800)

  • 61. Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: expert panel report.
    Johanson CE; Balster RL; Henningfield JE; Schuster CR; Anthony JC; Barthwell AG; Coleman JJ; Dart RC; Gorodetzky CW; O'Keeffe C; Sellers EM; Vocci F; Walsh SL
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1(Suppl 1):S65-71. PubMed ID: 19783383
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A pathway to improved prospective observational post-authorization safety studies.
    Kiri VA
    Drug Saf; 2012 Sep; 35(9):711-24. PubMed ID: 22861669
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Therapeutic risk management interventions: feasibility and effectiveness.
    Andrews E; Gilsenan A; Cook S
    J Am Pharm Assoc (2003); 2004; 44(4):491-500. PubMed ID: 15372870
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The respective roles of controlled clinical trials and cohort monitoring studies in the pre- and postmarketing assessment of drugs.
    Vray M; Hamelin B; Jaillon P;
    Therapie; 2005; 60(4):339-44, 345-9. PubMed ID: 16268434
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Benefit-risk reassessment of medicines: a retrospective analysis of all safety-related referral procedures in Europe during 2001-2012.
    Bouvy JC; Huinink L; De Bruin ML
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1004-14. PubMed ID: 27146035
    [TBL] [Abstract][Full Text] [Related]  

  • 66. New horizons in post-marketing surveillance.
    Waller P; Wood S
    Health Trends; 1993; 25(3):83. PubMed ID: 10131867
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Revision of the Renewals Procedure and the implementation of the sunset clause. BfArM's experience with the amended legislation].
    Horn M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):740-7. PubMed ID: 18584105
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pharmaceutical issues during the review of European Marketing Authorisation Applications in Malta
    Chetcuti M; Serracino-Inglott A; Flores G; Borg JJ
    Pharm Dev Technol; 2018 Jul; 23(6):561-572. PubMed ID: 28758819
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Assessing the impact of authorisation process as a regulatory tool in the European REACH regulation: A study on improving occupational safety for applying companies.
    Deubner HL; Walendzik G; Lüdeke A; Schlüter U
    Ann Work Expo Health; 2024 Jul; 68(6):617-625. PubMed ID: 38718166
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Post-market surveillance of GM foods: applicability and limitations of schemes used with pharmaceuticals and some non-GM novel foods.
    Wal JM; Hepburn PA; Lea LJ; Crevel RW
    Regul Toxicol Pharmacol; 2003 Aug; 38(1):98-104. PubMed ID: 12878059
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Post-marketing drug safety in the era of genomic medicine.
    Zavras AI
    J Dent Res; 2005 Feb; 84(2):105-6. PubMed ID: 15668326
    [No Abstract]   [Full Text] [Related]  

  • 72. Resolving a double standard for risk management of thalidomide: an evaluation of two different risk management programmes in Japan.
    Ooba N; Sato T; Watanabe H; Kubota K
    Drug Saf; 2010 Jan; 33(1):35-45. PubMed ID: 20000865
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Company observational post-marketing studies: drug risk assessment and drug research in special populations--a study-based analysis.
    Hasford J; Lamprecht T
    Eur J Clin Pharmacol; 1998 Jan; 53(5):369-71. PubMed ID: 9516039
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: linking quantitative risk assessment in pre-market licensure application safety data, post-market alert reports and formal epidemiological studies.
    O'Neill RT
    Stat Med; 1998 Aug 15-30; 17(15-16):1851-8; discussion 1859-62. PubMed ID: 9749452
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Quality risk management in pharmaceutical development.
    Charoo NA; Ali AA
    Drug Dev Ind Pharm; 2013 Jul; 39(7):947-60. PubMed ID: 22757979
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Practical risk management in early phase clinical trials.
    Coates S; Täubel J; Lorch U
    Eur J Clin Pharmacol; 2019 Apr; 75(4):483-496. PubMed ID: 30569285
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Clinical trials in oncology: deficits and proposals for solution].
    Schott G; Gökbuget N; Pachl H; Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2011; 105(9):657-64. PubMed ID: 22152423
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Guidelines for company-sponsored Safety Assessment of Marketed Medicines (SAMM) guidelines. Medicines Control Agency, Committee on Safety of Medicines, Royal College of General Practitioners, British Medical Association and Association of the British Pharmaceutical Industry (November 1993).
    Br J Clin Pharmacol; 1994 Aug; 38(2):95-7. PubMed ID: 7981019
    [No Abstract]   [Full Text] [Related]  

  • 79. Safety regulation for medicines and foodstuffs.
    Hirayama Y
    Asian Pac J Cancer Prev; 2010; 11(1):22-3. PubMed ID: 20593923
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [GPSP: good post-marketing study practice].
    Kumano S
    Nihon Yakurigaku Zasshi; 2012 Aug; 140(2):81-4. PubMed ID: 22878572
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.